Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension Study of SCIO-469 in Multiple Myeloma
NCT00095680Phase 2Completed
- Sponsor
- Scios Inc.
- Start
- Nov 2004
- Modality
- Small Molecules
01
Overview
Phase 2, open-label trial of talmapimod in multiple myeloma (MM) (2 arms), sponsored by Scios Inc. Primary endpoint: Rate of response during therapy. Started Nov 2004; status: completed.
02
Drugs
talmapimod
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00095680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00095680.